Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025).
“We look forward to sharing new clinical data that underscores how we are reimagining treatment for breast and prostate cancer, advancing highly effective therapies designed to improve quality of life, enable more personalized care and ultimately provide more time for cancer patients,” said Dushen Chetty, PhD, global head of oncology development, Novartis, Ad Interim. “Our ambition is to set new standards of care in some of the most prevalent cancers by pioneering novel technologies like radioligand therapy.”
Pluvicto (lutetium (177Lu) vipivotide tetraxetan): Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition) –#LBA6 –Presidential Symposium 2 (Proffered Paper session) –October 19, 2025 –16:30 – 18:15 CEST.
Pluvicto (lutetium (177Lu) vipivotide tetraxetan): Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore Study #2390P –Poster Presentation –October 18, 2025 –09:00 – 17:00 CEST.
Pluvicto (lutetium (177Lu) vipivotide tetraxetan): Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France– #2389P — Poster Presentation — October 18, 2025 — 09:00 – 17:00 CEST.
[225Ac]-PSMA-617: PSMAcTION trial-in-progress: A phase 2/3 randomized trial of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA therapy –#2516TiP –Poster Presentation -October 18, 2025 -9:00 – 17:00 CEST.
Kisqali (ribociclib): Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC): NATALEE 5-year outcomes — LBA14 — Proffered Paper session — October 17, 2025 — 4:00 – 15:30 CEST.
Kisqali (ribociclib): Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2- EBC: a subgroup analysis from the phase 3 NATALEE trial — #366P — Poster Presentation — October 20, 2025 –09:00 – 17:00 CEST.
Kisqali (ribociclib): A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx –#372P — Poster Presentation — October 20, 2025 — 09:00 – 17:00 CEST.
Kisqali (ribociclib): Real-world characteristics, treatments and outcomes of NATALEE and monarchE-eligible HR+/HER2- early breast cancer patients in the hospital district of Helsinki and Uusimaa (HUS), Finland –#360P –Poster Presentation — October 20, 2025 — 09:00 – 17:00 CEST.
Kisqali (ribociclib): Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2- BC: Preliminary Analysis of the SOLTI-RIBOLARIS Trial — #296O — Proffered Paper session –October 17, 2025 –14:00 – 15:30 CEST.
The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients.
As Novartis reimagines medicine, it collaborates with a wide range of patient advocacy groups and supports education, early cancer screening and diagnosis. With approximately 35 research and development projects across solid tumours, haematology and radioligand therapy (RLT), Novartis is committed to using technology, leading science and patient-centred research to deliver pioneering cancer care for all those in need.
Source : Pharmabiz
